BHC · Bausch Health Companies Inc · Stock research

Current Thesis

The leg on offer is a levered deleveraging-and-separation stub: a $2.41B equity market capitalisation sitting on $20,239M of long-term debt principal (10-Q, 2026-06-30), where operating momentum has been improving for thirteen straight quarters and the 87%-owned Bausch + Lomb stake is the largest single asset. The 2026-07-29 Q2 print was the accelerant — adjusted EPS $1.26 against a $1.04 consensus, revenue $2.852B against $2.661B, and a full-year sales guide lifted to $10.790–11.040B from $10.670–10.920B. Price took that to a 52-week high of $7.90 and then handed the move back: the 2026-08-21 close was $6.44, 18.5% below the high, RSI(14) 40.3. Nothing company-confirmed is dated inside the next 30 days, so the fade is happening in a news vacuum.

Bullish and bearish views on Bausch Health Companies Inc

The model's bull view on Bausch Health Companies Inc (BHC), in brief: Q2 2026 (2026-07-29): revenue $2,852M, +13% reported and +11% organic; adjusted EBITDA $1,075M, +28% YoY. The bear view: H1 2026 net loss of $1,165M against $90M of net income in H1 2025, driven by a $1,426M goodwill impairment in the Salix reporting unit attributed in the filing to failed Phase 3 trials (10-Q, 2026-06-30). Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-29): revenue $2,852M, +13% reported and +11% organic; adjusted EBITDA $1,075M, +28% YoY. Thirteenth consecutive quarter of revenue and adjusted EBITDA growth per the company's Q2 deck.
• Guidance raised, not reaffirmed. FY2026 revenue excluding B+L moved to $5.35–5.5B from $5.25–5.4B; adjusted EBITDA excluding B+L to $3.025–3.1B from $2.875–2.95B; adjusted operating cash flow to $1.4–1.475B from $1.2–1.275B (Q2 2026 slides).
• Salix carried the quarter. Segment revenue $758M, +21% YoY, of which Xifaxan was $664M, +26% YoY, on volume plus net-price optimisation after exiting Medicaid and 340B channels.
• Net debt fell $434M in the quarter to $13,653M (Q2 2026 materials). The separation of Bausch + Lomb is explicitly conditioned on "achievement of targeted debt leverage ratios" (10-Q, 2026-06-30), which makes every quarter of debt paydown a step toward the event the equity is priced for.
• The B+L stake is a marked asset, not an estimate. BHC indirectly holds 310,449,643 B+L common shares, roughly 87% of the class as of 2026-07-22 (B+L disclosure). B+L contributed $1,394M of Q2 revenue, +9% reported.
• Governance moved. Four new B+L directors were appointed effective 2026-08-05 at BHC's request, including BHC CEO Thomas Appio — control of the subsidiary board being tightened while the separation stays open.

Bear Case

• H1 2026 net loss of $1,165M against $90M of net income in H1 2025, driven by a $1,426M goodwill impairment in the Salix reporting unit attributed in the filing to failed Phase 3 trials (10-Q, 2026-06-30). The segment carrying the revenue beat is the segment that was written down.
• The Xifaxan clock is on the balance sheet. The Xifaxan intangible carried $808M with an estimated remaining useful life of 18 months at 2026-06-30 — i.e. management's own accounting runs the asset to roughly the end of 2027, matching the framing of 2027 guidance around exclusivity into 2028.
• The 2027 outlook steps down. Adjusted EBITDA guidance for 2027 was maintained at $2.7B on the Q2 call, below the $3.025–3.1B now guided for 2026 excluding B+L. Inference, not company language: the gap is the shape of the loss-of-exclusivity air pocket, and it arrives before any separation has been consummated.
• Litigation is not closed. The Federal Circuit upheld a decision barring Norwich from final ANDA approval until 2029-10-02, but on 2026-03-19 the FDA filed a letter with the DC Circuit advising that Actavis (Teva) had received final approval for generic rifaximin 550 mg. A single competitor with final approval changes the distribution of outcomes regardless of what the Norwich docket says.
• Interest expense of $798M in H1 2026 against long-term debt principal of $20,239M ($19,875M non-current, $866M current). Cash generation is real but a large share of it is spoken for before it reaches the equity.
• One third-party summary of the Q2 deck describes an approximately $50M second-half 2026 generic-competition headwind. That figure was not corroborated in the filing text reviewed here and should be checked against the company deck before it is used.

Setup & Price Structure

• Reference close 2026-08-21: $6.44. 52-week high $7.90; the shares sit 18.5% below it. Three-month price change +17.7%. RSI(14) 40.3.
• The shape is a beat-and-raise spike into $7.90 followed by roughly three weeks of give-back with no offsetting news. A stock that cannot hold a raised guide is telling you the marginal buyer for the separation story is priced, not absent — an observation about flow, not a forecast.
• RSI in the low 40s with price mid-retracement is neither washed out nor extended. There is no base yet; the structure that would matter is a higher low above the pre-print shelf, and it has not printed.
• Sell-side sponsorship is thin: consensus rating Hold across 7 analysts with a $7.50 consensus price target (stockanalysis.com, 2026-08-22). A beat-and-raise that leaves the consensus at Hold is a positioning fact worth more than the target itself.
• Positioning observables, stated plainly: no BHC insider Form 4 activity in the last 30 days in the filings reviewed; no equity issuance disclosed into the July strength; Paulson & Co's Q2 13F showed its equity book cut 17% to $2.58B with two positions exited (Benzinga, 2026-08-17) — that filing should be read directly for any BHC line change rather than inferred. No earnings date is imminent, so there is no print-risk premium currently compressing the tape.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-confirmed dated event identified. The window is empty of scheduled catalysts; September specialty-pharma conference appearances are common but no BHC date was confirmed in this research.
• ~2026-10-29 (est.): Q3 2026 results. Date unconfirmed; BHC has historically reported the third quarter in the last week of October.
• ~2026-10-29 (est.): Bausch + Lomb Q3 results. B+L reports separately and drove $1,394M of BHC's $2,852M Q2 consolidated revenue.
• 2028-01-01: the exclusivity date management's 2027 framing rests on. Not an event to trade, a modelling anchor that any interim court or FDA action can move forward.
• 2029-10-02: the date before which Norwich cannot obtain final ANDA approval per the affirmed Federal Circuit ruling.

What Would Change Our Mind

The structural break is the give-back completing: the July spike was the whole re-rate, and losing the shelf that the three-month advance was built on says the deleveraging story is being marked down rather than digested. A weekly close below $5.90 surrenders the bulk of that advance and ends the post-print leg as a tradeable structure.

Three non-price conditions would do the same work:

• A Q3 print that trims the FY2026 ex-B+L adjusted EBITDA range of $3.025–3.1B, or cuts the maintained 2027 $2.7B outlook.
• Any shortening of the Xifaxan intangible's stated 18-month remaining useful life, or a further Salix impairment following the $1,426M taken in H1 2026.
• Another quarter passing with no separation timeline disclosed and no movement on the stated leverage condition — the separation has been "in process" since 2022, and a fifth year of that is the narrative flipping from maturing to spent.

Conversely, the read strengthens on a disclosed leverage target being met, a filed Form 10 or equivalent separation step, or a Q3 that holds the raised range while net debt falls another increment from $13,653M.

Correlation Notes

• BLCO is the dominant factor. With 310,449,643 B+L shares held (~87%), a material share of BHC's asset value moves with Bausch + Lomb's own tape and guidance. BHC can fall on a B+L drawdown with zero BHC-specific news.
• Credit, not biotech. With $20,239M of long-term debt principal and $798M of H1 interest expense, BHC trades closer to a high-yield credit proxy than to XBI-style biotech beta; high-yield spread widening and refinancing windows matter more than sector sentiment.
• Loss-of-exclusivity cohort. The name shares a factor with specialty-pharma peers facing patent cliffs and generic-entry dockets; a court or FDA decision against any large branded product tends to reprice the group's litigation optionality.
• The equity is the thin tranche. $2.41B of market capitalisation against a $20.2B debt stack means enterprise-value moves of a few percent are amplified at the equity line in both directions. That is the mechanism behind both the July spike and the August fade.